comparemela.com

Latest Breaking News On - Natco pharma shares - Page 1 : comparemela.com

Comeback and re-rating supported by numbers? 5 pharma stocks with upside potential of up to 21%

Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant changes over the past decade. Marking a transition from a period of consolidation and valuation readjustment to one where the focus has shifted towards more sustainable and compliant operational practices. This transformation highlights a shift in the strategic approach adopted by pharmaceutical companies. Historically, the expansion strategies of many pharma companies were driven by optimistic powerpoint presentations forecasting market growth. However, this approach often overlooked the critical aspect of regulatory compliance, leading to various challenges. Over the years the Indian pharmaceutical industry has understood that regulatory compliance might be slightly more time consuming and also expensive but in long run it pays both for the real business growth and improving valuations. Will the industry remember the critical lesson is key.

GSFC, NBCC, Trent, Varroc, Natco Pharma: 20 top FY25 EPS upgrades among BSE500 firms

RMI scanner generates new buy signal in Nifty, these 4 stocks Do you own any?

Natco Pharma stock up 18% today, 26% in 4-day rally Nuvama shares target price

Natco Pharma share price target: Nuvama has raised its FY24E and FY25 EPS estimates for Natco Pharma by 21 per cent and 12 per cent, respectively, to factor in the beat, higher gRevlimid and lower tax; target at Rs 1,055.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.